LifeNet Health has introduced a decellularised placental membrane for wound healing, Matrion, paving way for new possibilities in patient care.
Matrion is currently available with select surgeons in the US and will be launched across the country by early next year.
Unlike other solutions, the new Matrion keeps all three layers of the placenta, including the trophoblast layer, fully intact from recovery to the application, protecting the robust extracellular matrix, the native growth factors, and other proteins.
With the trophoblast layer up to four times thicker than the amnion or chorion alone, it reduces chances of graft adhering to itself during placement.
It provides a full-thickness allograft biologic that supports optimal healing and handling.
LifeNet Health Wound Management and Surgical Reconstruction vice-president and general manager Mike Falcon said: “For years, clinicians have been forced to compromise when it comes to the placental graft they choose for their patients.
“We designed Matrion to protect the natural growth factors and strong structural matrix while resolving the handling challenges that are inherent in most placental grafts.”
Developed using LifeNet Health’s Matracell technology, Matrion provides the complete, decellularised trophoblast layer with up to 50% of the endogenous growth factors present in placental tissue.
Matracell delivers the membrane acellular, maintaining its biomechanical properties and growth factors while creating a porous structure to support neovascularisation.
The membrane is indicated as a protective barrier for covering diabetic foot ulcers, venous stasis ulcers, dehisced surgical wounds, and traumatic burns.
It joins Dermacell AWM, a proven healing solution for complex wounds in as little as one application.